top of page
Search

Intravitreal Pharmacotherapies for Diabetic Macular Edema

Article Name: Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.


What are the takeaway points from this article?

Intravitreal injections of anti-VEGF agents (including ranibizumab, aflibercept, bevacizumab) and intravitreal corticosteroid implants (including triamcinolone, dexamethasone, fluocinolone acetonide) are both effective in the management of diabetic macular edema (DME) resulting in functional and anatomic improvements. Evidence is lacking on their comparative effectiveness, although corticosteroid implants are associated with higher incidence of cataract progression and increased intraocular pressure. The authors suggest choice of therapy should be individualized for each patient until further evidence is available on the comparative efficacy of these therapies.


Reference:

Ehlers JP, Yeh S, Maguire MG, Smith JR, Mruthyunjaya P, Jain N, Kim LA, Weng CY, Flaxel CJ, Schoenberger SD, Kim SJ. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology (2021). https://doi.org/10.1016/j.ophtha.2021.07.009


Date Published: August 23, 2021


Summary by: Desiree Naude



80 views

Recent Posts

See All

Title of Article: Accuracy of Artificial Intelligence in Estimating Best-Corrected Visual Acuity From Fundus Photographs in Eyes With Diabetic Macular Edema What are the key takeaway points from this

Title of Article: Impact of Climate Change on Eye Diseases and Associated Economical Costs What are the key takeaway points from this article? Amidst the waves of smoke and haze from Canada’s wildfire

bottom of page